NICE guideline development group members also portrayed FeNO testing in essentialist terms as an instrument of progress, since it and other “objective” tests would enable asthma care to “catch up” with how other medical conditions are managed (heart failure diagnosis and monitoring, for example, is now based on brain naturietic peptide, BNP). This evidence concerns the gene NPPB and asthma.